ArticleScientific reports2018
Efficient inhibition of African swine fever virus replication by CRISPR/Cas9 targeting of the viral p30 gene (CP204L).
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 128 citations in OpenAlex.
- TGF-β/IFN-γ Antagonism in Subversion and Self-Defense of Phase II Coxiella burnetiiInfection and immunity · 2023Trial
- Genetically Modified and Gene-Edited Organisms-Objectives, Public Perception and Applications.Biology · 2026Review
- Exploiting Ubiquitination: African Swine Fever Virus-Mediated Recruitment of Host E3 Ligases During Viral Infection and Immune Regulation.Pathogens (Basel, Switzerland) · 2026Review
- Mechanistic insights and therapeutic advances in antiviral strategies against African swine fever virus.Acta pharmaceutica Sinica. B · 2026Review
- Article
- Pig Genome Editing for Agriculture: Achievements and Challenges.International journal of molecular sciences · 2025Review
- Structural and Functional Analysis of ASFV pI73R Reveals GNB1 Binding and Host Gene Modulation.International journal of molecular sciences · 2025Article
- The First CRISPR-Based Therapeutic (SL_1.52) for African Swine Fever Is Effective in Swine.Viruses · 2025Article
- Revisiting the early event of African swine fever virus DNA replication.Journal of virology · 2025Article
- Single-Cell Atlas of Spleen Remodeling Reveals Macrophage Subset-Driven ASFV Pathogenesis.Biology · 2025Article
- A synthetic genomics-based African swine fever virus engineering platform.Science advances · 2025Article
- Gene Editing for Enhanced Swine Production: Current Advances and Prospects.Animals : an open access journal from MDPI · 2025Review
- Exploring antiviral strategies to combat African swine fever.FEMS microbiology reviews · 2025Review
- Infection Characteristics, Transcriptomics, and Metabolomics of African Swine Fever Virus SY-1 Strain in Orally Infected Weaned Landrace Piglets.Transboundary and emerging diseases · 2025Article
- The Potential of Disabled Infectious Single Cycle (DISC) Virus Platforms for Next Generation African Swine Fever Vaccine Development.Transboundary and emerging diseases · 2025Review
- Insights into the Role of VPS39 and Its Interaction with CP204L and A137R in ASFV Infection.Viruses · 2024Article
- Testing multiplexed anti-ASFV CRISPR-Cas9 in reducing African swine fever virus.Microbiology spectrum · 2024Article
- Advancement of animal and poultry nutrition: Harnessing the power of CRISPR-Cas genome editing technology.Journal of advanced veterinary and animal research · 2024Article
- SNX32 is a host restriction factor that degrades African swine fever virus CP204L via the RAB1B-dependent autophagy pathway.Journal of virology · 2024Article
- Identification of the p34 Protein of African Swine Fever Virus as a Novel Viral Antigen with Protection Potential.Viruses · 2023Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever is a devastating viral disease of domestic and wild pigs against which no vaccine or therapy is available. Therefore, we applied the CRISPR (clustered regularly interspaced short palindromic repeats) - Cas9 nuclease system to target the double-stranded DNA genome of African swine fever virus (ASFV). To this end, a permissive wild boar lung (WSL) cell line was modified by stable transfection with a plasmid encoding Cas9 and a guide RNA targeting codons 71 to 78 of the phosphoprotein p30 gene (CP204L) of ASFV. Due to targeted Cas9 cleavage of the virus genome, plaque formation of ASFV was completely abrogated and virus yields were reduced by four orders of magnitude. The specificity of these effects could be demonstrated by using a natural ASFV isolate and escape mutants possessing nucleotide exchanges within the target sequence, which were not inhibited in the Cas9-expressing cell line. Growth of the cell line was not affected by transgene expression which, as well as virus inhibition, proved to be stable over at least 50 passages. Thus, CRISPR-Cas9 mediated targeting of the ASFV p30 gene is a valid strategy to convey resistance against ASF infection, which may also be applied in its natural animal host.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.